KRAS and neoplasm: These findings support the use of <i>KRAS</i>-G12C and <i>PIK3CA</i>-Q546K as cost-effective, accessible tumor biomarkers for aiding in MAP diagnosis and <i>MUTYH</i> VUS reclassification, particularly in settings with limited access to whole-exome/genome mutational signature analysis.